Literature DB >> 10510460

The effects of endomorphin-1 and endomorphin-2 in CHO cells expressing recombinant mu-opioid receptors and SH-SY5Y cells.

C Harrison1, S McNulty, D Smart, D J Rowbotham, D K Grandy, L A Devi, D G Lambert.   

Abstract

1 Endomorphin-1 and -2 (E-1/E-2) have been proposed as endogenous ligands for the mu-opioid receptor. The aims of this study are to characterize the binding of E-1/E-2 and the subsequent effects on cyclic AMP formation and [Ca2+]i levels in SH-SY5Y and Chinese hamster ovary (CHO) cells expressing endogenous and recombinant mu-opioid receptors. 2 E-1 displaced [3H]-diprenorphine ([3H]-DPN) binding in CHO micro and SH-SY5Y membranes with pKi values of 8.02+/-0.09 and 8.54+/-0.13 respectively. E-2 displaced [3H]-DPN binding in CHOmu and SH-SY5Y cells with pKi values of 7.82+/-0.11 and 8.43+/-0.13 respectively. E-1/E-2 bound weakly to CHOdelta and CHOkappa membranes, with IC50 values of greater than 10 microM. 3 In CHOmu cells, E-1/E-2 inhibited forskolin (1 microM) stimulated cyclic AMP formation with pIC50 values of 8.03+/-0.16 (Imax = 53.0+/-9. 3%) and 8.15+/-0.24 (Imax = 56.3+/-3.8%) respectively. In SH-SY5Y cells E1/E2 inhibited forskolin stimulated cyclic AMP formation with pIC50 values of 7.72+/-0.13 (Imax=46.9+/-5.6%) and 8.11+/-0.31 (Imax = 40.2+/-2.8%) respectively. 4 E-1/E-2 (1 microM) increased [Ca2+]i in fura-2 loaded CHOmu cell suspensions in a thapsigargin sensitive and naloxone reversible manner. Mean increases observed were 106+/-28 and 69+/-6.7 nM respectively. In single adherent cells E-1/E-2 (1 microM) increased [Ca2+]i with a mean 340/380 ratio change of 0.81+/-0.09 and 0.40+/-0.08 ratio units respectively. E-1/E-2 failed to increase intracellular calcium in CHOdelta, CHOkappa and SH-SY5Y cells. 5 These data show that E-1/E-2 bind with high affinity and selectivity to mu-opioid receptors and modulate signal transduction pathways typical of opioids. This provides further evidence that these two peptides may be endogenous ligands at the mu-opioid receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510460      PMCID: PMC1571641          DOI: 10.1038/sj.bjp.0702798

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  Endomorphins inhibit high-threshold Ca2+ channel currents in rodent NG108-15 cells overexpressing mu-opioid receptors.

Authors:  H Higashida; N Hoshi; R Knijnik; J E Zadina; A J Kastin
Journal:  J Physiol       Date:  1998-02-15       Impact factor: 5.182

2.  Endomorphin-stimulated [35S]GTPgammaS binding in rat brain: evidence for partial agonist activity at mu-opioid receptors.

Authors:  L J Sim; Q Liu; S R Childers; D E Selley
Journal:  J Neurochem       Date:  1998-04       Impact factor: 5.372

3.  Immunoreactivity for endomorphin-2 occurs in primary afferents in rats and monkey.

Authors:  T L Pierce; M D Grahek; M W Wessendorf
Journal:  Neuroreport       Date:  1998-02-16       Impact factor: 1.837

4.  The endogenous mu-opioid agonists, endomorphin 1 and 2, have vasodilator activity in the hindquarters vascular bed of the rat.

Authors:  H C Champion; J E Zadina; A J Kastin; P J Kadowitz
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

5.  Ca2+ channel inhibition by endomorphins via the cloned mu-opioid receptor expressed in NG108-15 cells.

Authors:  H Mima; H Morikawa; K Fukuda; S Kato; T Shoda; K Mori
Journal:  Eur J Pharmacol       Date:  1997-12-11       Impact factor: 4.432

6.  Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I.

Authors:  N T Burford; L M Tolbert; W Sadee
Journal:  Eur J Pharmacol       Date:  1998-01-19       Impact factor: 4.432

7.  Endomorphin 1 and 2, endogenous mu-opioid agonists, decrease systemic arterial pressure in the rat.

Authors:  M A Czapla; H C Champion; J E Zadina; A J Kastin; L Hackler; L J Ge; P J Kadowitz
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

8.  Localization of endomorphin-2-like immunoreactivity in the rat medulla and spinal cord.

Authors:  S Martin-Schild; J E Zadina; A A Gerall; S Vigh; A J Kastin
Journal:  Peptides       Date:  1997       Impact factor: 3.750

9.  Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 from human brain cortex.

Authors:  L Hackler; J E Zadina; L J Ge; A J Kastin
Journal:  Peptides       Date:  1997       Impact factor: 3.750

10.  Endomorphin 1 and 2, endogenous ligands for the mu-opioid receptor, decrease cardiac output, and total peripheral resistance in the rat.

Authors:  H C Champion; J E Zadina; A J Kastin; L Hackler; L J Ge; P J Kadowitz
Journal:  Peptides       Date:  1997       Impact factor: 3.750

View more
  7 in total

Review 1.  Visualizing activation of opioid circuits by internalization of G protein-coupled receptors.

Authors:  Kevin Sinchak; Paul Micevych
Journal:  Mol Neurobiol       Date:  2003-04       Impact factor: 5.590

2.  G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding.

Authors:  Ivone Gomes; Adriaan P Ijzerman; Kai Ye; Emeline L Maillet; Lakshmi A Devi
Journal:  Mol Pharmacol       Date:  2011-03-17       Impact factor: 4.436

3.  Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor.

Authors:  C Harrison; D J Rowbotham; D K Grandy; D G Lambert
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

4.  Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides.

Authors:  Yasuko Koda; Mark Del Borgo; Susanne T Wessling; Lawrence H Lazarus; Yoshio Okada; Istvan Toth; Joanne T Blanchfield
Journal:  Bioorg Med Chem       Date:  2008-04-15       Impact factor: 3.641

5.  Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor.

Authors:  Michael Wallisch; Cole S Nelson; Julia M Mulvaney; Heather S Hernandez; Sue Ann Smith; George D Olsen
Journal:  Biochem Pharmacol       Date:  2007-02-12       Impact factor: 5.858

6.  Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation.

Authors:  Pegah Varamini; Friederike M Mansfeld; Joanne T Blanchfield; Bruce D Wyse; Maree T Smith; Istvan Toth
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

7.  Food-Derived Hemorphins Cross Intestinal and Blood-Brain Barriers In Vitro.

Authors:  Dorothée Domenger; Benoit Cudennec; Mostafa Kouach; Véronique Touche; Christophe Landry; Jean Lesage; Fabien Gosselet; Sophie Lestavel; Jean-François Goossens; Pascal Dhulster; Rozenn Ravallec
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-10       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.